Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer

Abstract

A subset of bladder tumors have genomic features suggestive of HRD and therefore may be more likely to benefit from therapies such as platinum agents and PARP inhibitors that target tumor HRD.